Berkeley Investments’ life science project, 176 Lincoln in the Allston section of Boston, MA, has been fully approved. The transit-oriented, mixed-use development will encompass Class A lab and R&D space, office space and residential units with immediate access to downtown Boston and Harvard Square in Cambridge.

The 176 Lincoln project will rise on a five-acre site that will incorporate two acres of landscaped open space. The two main commercial buildings will include 720,000 square feet of lab, R&D and office space with branding opportunities.

In addition, the project will include on-site housing, including 252 apartments with 10 live/work units for artists and walkable access to the Charles River public parks, trails, and outdoor amenities. The project is aiming to achieve Passive House certification.

Berkeley Investments’ Boston-area development pipeline includes a fully entitled, shovel-ready 203,000-square-foot cGMP/biomanufacturing development in Billerica; a Class-A life science redevelopment in Watertown and a 350,000-square-foot transit-oriented development project in Malden.